Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
Clinical trial NCT07258745 · RECRUITING
Trial details
- NCT number
- NCT07258745
- Sponsor
- Chong Kun Dang Pharmaceutical
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-26
- Primary completion
- 2026-09-30
- Enrollment
- 213
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.